SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9459)3/30/1999 10:50:00 PM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
Alert>according to EM the hu1124 study mentioned is a ongoing P1
dosing study of hu1124. Thats right P1.
This continues even as xoma and gne perhaps discuss terms and prospects. I would guess xomadog has a good feeling for prospects in regards to hu1124. Dogs do sniff.
VBG (not said unkindly)



To: Bluegreen who wrote (9459)3/30/1999 10:55:00 PM
From: LarryS  Respond to of 17367
 
Your post about the safety of new drugs
was interesting but shouldn't effect XOMA.
If there is only ONE thing we know for certain
about Neuprex, we know it is safe.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News